HR-10272-119
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sponsored by Lance Gooden (R-TX)
What it does
This bill would classify synthetic forms of 7-hydroxymitragynine (7-OH) and mitragynine pseudoindoxyl as Schedule I controlled substances, with an exemption for naturally occurring trace amounts in kratom products below specific concentration thresholds. It would also create a new enforcement framework treating certain "emerging synthetic opioids" that are more potent than morphine as Schedule I substances solely for manufacturing, distribution, and importation offenses, while explicitly barring prosecution for simple possession or personal use of these substances.
Who benefits
Consumers of traditional low-concentration kratom products, who would remain legally protected under the exemption thresholds; public health officials and poison control centers concerned about concentrated 7-OH products marketed as "gas station heroin"; law enforcement and prosecutors gaining a new tool against manufacturers and distributors of high-potency synthetic opioid analogs; and communities affected by opioid-related overdoses involving these substances.
Who is hurt
Manufacturers and distributors of concentrated 7-OH and mitragynine pseudoindoxyl products, who would face federal prosecution and lose a currently unregulated market; retailers (including gas stations and smoke shops) that sell these concentrated products; the broader kratom industry, which may face increased scrutiny and testing costs to prove products fall under exemption thresholds; and researchers who must navigate new regulatory classifications for related compounds.
Supporters argue
Supporters argue that concentrated 7-OH products, sometimes called "gas station heroin," are being marketed and sold with little regulation despite exhibiting opioid-like potency and addiction risk comparable to or exceeding morphine, citing rising poison control calls and case reports of dependence. They contend the bill targets commercial manufacturers and distributors rather than individual users, preserving access to traditional low-concentration kratom while closing a dangerous regulatory gap that has let synthetic opioid analogs proliferate outside the Controlled Substances Act.
Opponents argue
Opponents argue that scheduling 7-OH and mitragynine pseudoindoxyl, even in synthetic or concentrated form, risks harming kratom consumers who use these products for pain management or opioid withdrawal, particularly given the ambiguity in the concentration thresholds and how "naturally occurring" versus "synthesized" compounds will be distinguished in practice. They contend the bill could push the kratom industry toward the same unregulated black market dynamics that have historically increased overdose risk with other substances subject to prohibition.